Not yet recruiting
Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients
NCT07004413
- Conditions
- Colonic Diseases, Colorectal Cancer Metastatic, Colorectal Neoplasms, +9 more
- Locations
-
- Charite University, Berlin Berlin, Germany